'Botox War' Concluded After 5 Years... US ITC Orders Daewoong Pharmaceutical Import Ban for 21 Months (Update)
[Asia Economy Reporter Cho Hyun-ui] The U.S. International Trade Commission (ITC) ruled in favor of Medytox on the 16th (local time) in the dispute over botulinum strains between Medytox and Daewoong Pharmaceutical.
The ITC stated that "Daewoong Pharmaceutical violated Section 337 of the Tariff Act" and issued a 21-month import ban on Daewoong Pharmaceutical's 'Nabota.'
The 'Botox war' between Medytox and Daewoong Pharmaceutical began in 2016. Medytox has claimed that Daewoong Pharmaceutical stole its strains and pharmaceutical manufacturing technology when launching Nabota.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
In January last year, Medytox officially filed a complaint with the ITC against Daewoong Pharmaceutical for trade secret infringement. In a preliminary ruling in July this year, the ITC sided with Medytox and recommended a 10-year import ban on Nabota. Then, in the final ruling on this day, five months later, the ITC again ruled in favor of Medytox and ordered a 21-month import ban on Nabota.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
